DEF: BioRestorative Therapies Seeks Share Increase for Growth

BioRestorative Therapies is holding a special meeting on May 26, 2026, to vote on increasing authorized common stock from 75 million to 1.5 billion shares, aiming to fund clinical trials and general corporate needs.

Summary

• BioRestorative Therapies, Inc. is convening a Special Meeting of Stockholders on May 26, 2026, to vote on a proposal to amend its Articles of Incorporation.
• The primary purpose of the amendment is to increase the number of authorized shares of common stock from 75,000,000 to 1,500,000,000.
• This increase is intended to provide the company with future flexibility for general corporate purposes, including raising capital for clinical trials, pre-clinical research, business initiatives, employee benefit programs, and potential acquisitions.
• The company also plans to seek additional capital through private placements or public offerings of its common stock or related securities, with proceeds earmarked for its BRTX-100 clinical trials, ThermoStem Program, biocosmeceuticals platform, and general working capital.
• A second proposal allows for the adjournment of the meeting if necessary to solicit further proxies for the primary proposal.
• Stockholders of record as of April 6, 2026, are eligible to vote.
• The company received a notice from Nasdaq on March 26, 2026, for non-compliance with the minimum bid price requirement of $1.00 per share and has until September 22, 2026, to regain compliance.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a cautious sentiment due to the Nasdaq non-compliance and the potential for significant shareholder dilution, despite the strategic necessity of increasing authorized shares for future funding.

Positives

• The proposed increase in authorized shares provides significant financial flexibility for future growth, including funding for clinical trials and research.
• The company has a clear strategy for utilizing potential capital raises, focusing on key development programs like BRTX-100 and the ThermoStem Program.
• Management and directors collectively hold a substantial portion of the outstanding shares (13.6%), indicating alignment with shareholder interests.
• The company is actively seeking to address Nasdaq's continued listing requirements, demonstrating a commitment to maintaining its stock exchange listing.

Negatives

• The company is not in compliance with Nasdaq's minimum bid price requirement and faces a deadline to regain compliance, posing a risk to its listing.
• The proposed increase in authorized shares could lead to significant dilution for existing shareholders upon future issuances.
• There are no definitive agreements in place for future capital raises, and no assurance can be given that such transactions will be consummated on commercially reasonable terms.
• The company's ability to satisfy Nasdaq's continued listing requirements beyond the minimum bid price is not guaranteed.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement by September 22, 2026, could result in delisting from the Nasdaq Capital Market.
• Future issuances of stock to raise capital could dilute the ownership percentage of existing shareholders.
• The company's ability to secure future financing on favorable terms is uncertain.
• The company's business initiatives, including clinical trials and product development, are subject to inherent risks and uncertainties.
• The potential use of additional authorized shares as a defensive tactic against hostile takeovers, although not currently threatened, could impact shareholder value in the future.

Future Outlook

The company intends to raise additional capital through the issuance of common stock or related securities in one or more private placement transactions or public offerings. Proceeds are intended for clinical trials with BRTX-100, pre-clinical research for the ThermoStem Program, development of its biocosmeceuticals platform, and general corporate and working capital purposes. The company must also regain compliance with Nasdaq's minimum bid price requirement by September 22, 2026.

Management Comments

• "The availability of additional authorized shares of common stock will provide us with the flexibility in the future to issue shares of our common stock (i) for general corporate purposes, including raising additional capital in connection with our clinical trials and other business initiatives as discussed below, (ii) in connection with present and future employee benefit programs, (iii) in connection with the establishment of reserves with regard to the conversion of options, warrants, preferred stock and indebtedness, and (iv) in connection with acquisitions of companies or assets."
• "Although our Board has no current plans to utilize the additional authorized shares of common stock to entrench present management, it may, in the future, be able to use the additional common stock as a defensive tactic against hostile takeover attempts."
• "We are considering various alternatives in order to satisfy the continued listing requirement with regard to minimum bid price."

Industry Context

StockSavvy.ai notes that the proposed increase in authorized shares is a common strategy for biotechnology and clinical-stage companies needing to secure funding for ongoing research and development. However, the Nasdaq non-compliance highlights the significant pressure these companies face to maintain market capitalization and investor confidence.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution of ownership interest upon future issuance of new shares; potential delisting from Nasdaq if minimum bid price is not met.
• Management: Increased flexibility to pursue strategic initiatives and capital raises; potential for entrenchment if shares are used defensively (though management states no current plans).
• Creditors/Suppliers: Indirect impact through the company's financial health and ability to fund operations.
• Employees: Potential for future stock-based compensation and job security tied to the company's success and continued listing.

Next Steps

• Stockholders to vote on the proposed amendment to increase authorized shares.
• Stockholders to vote on the proposal to adjourn the meeting if necessary.
• The company must regain compliance with Nasdaq's minimum bid price requirement by September 22, 2026.
• The company may pursue private placements or public offerings to raise capital if the share increase is approved.

Key Dates

Recommendation

A 'hold' recommendation is advised due to the critical Nasdaq compliance issue and the significant dilution risk associated with the proposed share increase. While the company needs capital flexibility, the immediate threat of delisting and the potential for substantial dilution outweigh the speculative upside from future capital raises at this juncture. Investors should await clarity on Nasdaq compliance and the terms of any future capital raises before considering a more aggressive stance.

Keywords

BioRestorative Therapies, DEF 14A, Proxy Statement, Special Meeting, Authorized Shares, Common Stock, Capital Raise, Clinical Trials, BRTX-100, Nasdaq Compliance, Shareholder Vote, Dilution